First plant for production of infusion solutions opened in Kyrgyzstan

The first import-substituting production of sterile medicines in the form of infusion solutions and injections in ampoules, meeting the requirements of international GMP standards, has been opened in Kyrgyzstan, the Russian-Kyrgyz Development Fund (RKDF) reported.

The plant was built with $7.7 million in financial support from the RKDF.

The production capacity of the new plant is 18 million vials and 5.7 million ampoule packages per year, which will fully cover the demand of the Kyrgyz healthcare system for infusion solutions, ampoule injections and eye drops.

“The opening of this plant is a crucial step in the development of the pharmaceutical industry in Kyrgyzstan. RKDF not only provided financing, but also provided substantial technical assistance at the design stage of the plant, which made it possible to create a modern production facility that meets international standards,” RKDF Chairman Artem Novikov said.

The plant is the first enterprise in Kyrgyzstan that produces sterile medicines under conditions of fully automated production. Thanks to modern technologies, it ensures the safety and quality of products at all stages, from the production of pharmaceutical polyethylene to the packaging of finished products.